CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines

Theoretically, small molecule CDK4/6 inhibitors (CDK4/6is) represent a logical therapeutic option in non-small cell lung cancers since most of these malignancies have wildtype RB, the key target of CDKs and master regulator of the cell cycle. Unfortunately, CDK4/6is are found to have limited clinica...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS One
Hlavní autoři: Wright, Gabriela M., Gimbrone, Nick T., Sarcar, Bhaswati, Percy, Trent R., Gordián, Edna R., Kinose, Fumi, Sumi, Natália J., Rix, Uwe, Cress, W. Douglas
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2021
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8211232/
https://ncbi.nlm.nih.gov/pubmed/34138895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0252927
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky